Neulasta®

DRUG4 trials

Sponsors

Sandoz, Lupin Ltd., Prolong Pharmaceuticals

Conditions

Breast CancerBreast NeoplasmsChemotherapeutic ToxicityChemotherapy-induced NeutropeniaNeutropenic Complications

Phase 2

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

TerminatedNCT03559387

Prolong PharmaceuticalsChemotherapy-induced Neutropenia

Start: 2017-08-03End: 2018-05-22Updated: 2019-02-12

Phase 3

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

CompletedNCT01516736

SandozBreast Cancer, Chemotherapy-induced Neutropenia

Start: 2012-03-31End: 2013-12-31Updated: 2017-08-30

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®

CompletedNCT01735175

SandozBreast Neoplasms, Chemotherapeutic Toxicity, Chemotherapy-induced Neutropenia +1

Start: 2012-06-30End: 2014-02-28Updated: 2017-08-07

Phase 4

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

CompletedNCT03511378

Lupin Ltd.Breast Cancer

Start: 2018-03-06End: 2019-01-09Updated: 2021-06-15

Related Papers

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

2017-09-019 citations